Sci Immunol: 研究发现轻度或无症状COVID-19感染者可形成持久免疫

2020-12-28 MedSci原创 MedSci原创

来自伦敦玛丽女王大学的科学家们最近一项新研究发现,轻度或无症状的COVID-19感染者在发生感染后的4个月里可产生保护性免疫力。

来自伦敦玛丽女王大学的科学家们最近一项新研究发现,轻度或无症状的COVID-19感染者在发生感染后的4个月里可产生保护性免疫力。

研究分析了自今年3月以来136名携带COVID-19病毒的无症状或有轻度症状的伦敦医护人员的抗体和T细胞反应。这篇文章于1223日发表在《Science Immunology》杂志上。

DOI: 10.1126/sciimmunol.abf3698

研究人员发现89%的医护人员在感染16-18周后携带中和抗体。

不过他们发现大多数人有能够识别病毒的多个不同部分T,但他们的T细胞反应和抗体产生并不常常一起发生,有些人产生了T细胞免疫,但并没有发现抗体,反之亦然。

Credit: Pixabay/CC0 Public Domain

玛丽女王学院的博士后研究助理Joseph Gibbons说:我们对伦敦医院医护人员感染SARS-CoV-2的研究表明,在感染4个月后,大约90%的人都检测出阻断病毒的抗体。更令人鼓舞的是, 66%的医护人员体内这些保护性抗体的水平很高,而且这种强有力的抗体反应还得到了T细胞的补充。

这意味着,如果你被感染,很有可能会产生抗体和T细胞,如果你再次遇到病毒,这些抗体和T细胞可能会提供一些保护。

他们还发现,在表现出典型症状的患者中,T细胞反应往往更高,而无症状感染者T细胞免疫较弱弱,但抗体反应相当。

玛丽女王学院的博士后研究科学家Corinna Pade博士说:我们通过对无症状和轻度症状患者病例的研究,对人体感染SARS-CoV-2四个月后免疫持久性有了积极的认识。大约90%左右的人拥有较强的阻止病毒进入,同时还有可以干扰病毒不同反应的T细胞。这是一个重要的发现,因为感染COVID-19仅出现轻微症状甚至没有症状的情况是非常普遍的。如此丰富的免疫反应也为持久效力疫苗的研制带来了希望。

参考资料:https://medicalxpress.com/news/2020-12-evidence-immunity-mild-asymptomatic-covid-.html

原始出处:Catherine J. Reynolds, Leo Swadling, Joseph M. Gibbons, et al.  Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753572, encodeId=5e651e535726e, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun May 09 22:04:59 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485139, encodeId=e2f11485139b5, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Dec 30 10:04:59 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911737, encodeId=0b1e911e37b8, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201228/d16ceba3c34344cdbc38bd65be51fbb6/900ebeb6e79b4d58ae5f94cdaccabe30.jpg, createdBy=4d445448349, createdName=ms6000000074856602, createdTime=Mon Dec 28 21:42:22 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911690, encodeId=96fd91169060, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 28 19:15:42 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753572, encodeId=5e651e535726e, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun May 09 22:04:59 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485139, encodeId=e2f11485139b5, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Dec 30 10:04:59 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911737, encodeId=0b1e911e37b8, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201228/d16ceba3c34344cdbc38bd65be51fbb6/900ebeb6e79b4d58ae5f94cdaccabe30.jpg, createdBy=4d445448349, createdName=ms6000000074856602, createdTime=Mon Dec 28 21:42:22 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911690, encodeId=96fd91169060, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 28 19:15:42 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753572, encodeId=5e651e535726e, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun May 09 22:04:59 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485139, encodeId=e2f11485139b5, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Dec 30 10:04:59 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911737, encodeId=0b1e911e37b8, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201228/d16ceba3c34344cdbc38bd65be51fbb6/900ebeb6e79b4d58ae5f94cdaccabe30.jpg, createdBy=4d445448349, createdName=ms6000000074856602, createdTime=Mon Dec 28 21:42:22 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911690, encodeId=96fd91169060, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 28 19:15:42 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
    2020-12-28 ms6000000074856602

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1753572, encodeId=5e651e535726e, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun May 09 22:04:59 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485139, encodeId=e2f11485139b5, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Dec 30 10:04:59 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911737, encodeId=0b1e911e37b8, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201228/d16ceba3c34344cdbc38bd65be51fbb6/900ebeb6e79b4d58ae5f94cdaccabe30.jpg, createdBy=4d445448349, createdName=ms6000000074856602, createdTime=Mon Dec 28 21:42:22 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911690, encodeId=96fd91169060, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 28 19:15:42 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
    2020-12-28 jyzxjiangqin

    好文章!

    0

相关资讯

NAT COMMUN:在没有体液免疫的情况下,用瑞德西韦治疗COVID-19的病例报告

由于缺乏有效的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗病毒治疗,2019年冠状病毒病(COVID-19)大流行的应对措施受到了阻碍。原药核苷类似物瑞德西韦是病毒RNA依赖性RNA聚合酶(

高福院士团队新冠病毒重组蛋白亚单位疫苗启动Ⅲ期临床试验

11月18日,中国科学院微生物研究所高福院士团队与重庆智飞生物制品股份有限公司(智飞生物)联合研制的新冠病毒重组蛋白亚单位疫苗,在湖南省湘潭市湘潭县开始国内部分的III期临床试验。

从农民逆袭成为院士,他率先判断出新冠病毒,研究成果在全世界应用

他从事传染病防控工作40余年,多次率领团队从容应对我国重大传染病的疫情,加强基层应对疫情的能力,也见证了我国传染病预防的发展;他所取得的科研成果,提高了疫情控制的科技水平和科技含量,也在国际著名杂志发

全美急救系统濒临崩溃,许多急救人员工作中感染新冠

据美国全国广播公司报道,日前美国急救协会在写给美国卫生与公众服务部的信中称,全美911急救系统已处于崩溃边缘。由于新冠肺炎疫情恶化,新增病例激增,美国多家急救机构工作量猛增,支出大幅上涨;同时,许多急

CELL:COVID-19中和抗体预测患者生死

研究人员在CELL杂志发文,其检查了113例COVID-19患者的抗体反应,发现导致插管或死亡的严重病例表现出炎症标志物增加、淋巴细胞减少、促炎细胞因子和高抗RBD抗体水平的增加。

全新新冠病毒突变确认:亲和力提高1000倍,传播力提高70%,还能抗原漂移

在突变毒株的多次“狼来了”之后,这次狼真是来了。